425: Biomotion Sciences to Go Public via Merger with Moringa Acquisition Corp, Advancing KRAS-Targeted Cancer Therapies

Biomotion Sciences is set to merge with Moringa Acquisition Corp, aiming to advance its siRNA platform technology targeting KRAS-driven cancers, with a focus on its lead candidate SIL-204.

Summary

• Biomotion Sciences is merging with Moringa Acquisition Corp to become a publicly listed company (PubCo) on Nasdaq under the ticker SLXN.
• The company is focused on developing proprietary treatments for KRAS-driven cancers using its siRNA platform technology.
• Their lead candidate, SIL-204, is an optimized version of LODER, designed to silence oncogenes and prevent the production of mutated KRAS proteins.
• A Phase 2 trial of LODER showed a 9.3-month improvement in overall survival when combined with chemotherapy compared to chemotherapy alone in patients with KRAS G12D/V mutations.
• SIL-204 is designed for intratumoral administration, potentially leading to higher drug concentrations in the tumor and lower systemic exposure.
• The company plans to initiate toxicology studies for SIL-204 and submit a Clinical Trial Application (CTA) in the EU, with a Phase 2/3 trial planned for 2026.
• Biomotion Sciences has a strong IP portfolio with exclusivity through December 2043, with potential extensions.

Sentiment

Score: 7

Explanation: The document presents a promising clinical-stage company with a novel approach to targeting KRAS-driven cancers. The Phase 2 results are encouraging, and the planned merger provides the necessary capital to advance the lead candidate. However, the company faces significant risks associated with drug development and regulatory approval.

Positives

• The siRNA platform technology is designed to silence oncogenes and prevent the production of mutated KRAS proteins.
• The Phase 2 trial of LODER showed a 9.3-month improvement in overall survival when combined with chemotherapy compared to chemotherapy alone in patients with KRAS G12D/V mutations.
• SIL-204 has enhanced siRNA stability and an improved extended-release profile compared to LODER.
• Intratumoral administration may overcome limitations of systemic delivery, leading to higher drug concentrations in the tumor and lower systemic exposure.
• The company has received positive guidance from the German regulatory agency on the proposed Phase 2/3 trial design.
• The IP portfolio provides exclusivity through December 2043, with potential extensions.
• SIL-204 is stable in vitro for over 48 hours in human serum and in vivo in rats for five hours.

Negatives

• Silexion is a development-stage company and has a limited operating history.
• Silexion has never generated any revenue from product sales and may never be profitable.
• Pubco will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to Pubcos shareholders.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products.

Risks

• The Business Combination may not be completed.
• Moringa may not succeed at having the Moringa ordinary shares and Moringa warrants remain listed on Nasdaq until completion of the Business Combination.
• The ability to fulfill the Nasdaq listing conditions and/or maintain the listing of Pubco ordinary shares on the Nasdaq following the Business Combination is not guaranteed.
• Silexion is a development-stage company with a limited operating history.
• Silexion has never generated revenue and may never be profitable.
• Pubco will need to raise substantial additional funding, which may not be available on acceptable terms.
• The RNAi therapeutic approach is unproven for oncology.
• Silexion lacks experience in producing product candidates at commercial levels and has no marketing/sales organization.
• Moringa's sponsor and affiliates have potential conflicts of interest.
• Moringa's shareholders who do not redeem their Moringa Class A ordinary shares will have a reduced, minority voting interest after the Business Combination and will exercise less influence over management.
• The SPAC merger may be a taxable transaction for U.S. federal income tax purposes to U.S. Holders of Moringa Class A ordinary shares and Moringa public warrants.
• Silexion may issue additional Pubco ordinary shares or other equity securities without your approval, including shares underlying warrants and note shares, which would dilute your ownership interest and may depress the market price of the Pubco ordinary shares.

Future Outlook

Biomotion Sciences plans to advance SIL-204 through clinical trials, targeting regulatory submissions and approvals, and ultimately commercialize its KRAS-targeted therapies.

Industry Context

The announcement comes amid growing interest in RNAi therapeutics for cancer, particularly those targeting oncogenic drivers like KRAS. Several companies are developing KRAS inhibitors, but Biomotion Sciences' approach focuses on silencing the gene at the production stage, which they believe is a more efficient and safer approach.

Comparison to Industry Standards

• The document mentions KRAS G12C treatments, indicating a comparison to companies like Amgen, which has developed a KRAS G12C inhibitor (Lumakras).
• The document references Alnylam and its siRNA drugs (Givlaari, Lumasiran, Vutrisiran, Inclisiran) as examples of approved siRNA therapies, suggesting a benchmark for safety and efficacy.
• The document compares the half-life of SIL-204 in rats and human plasma to those of Alnylam's siRNA drugs, potentially positioning SIL-204 as having superior stability.

Stakeholder Impact

• Shareholders of Moringa will vote on the proposed Business Combination.
• Patients with KRAS-driven cancers may benefit from the development of new treatment options.
• Employees of Silexion and Moringa may experience changes as a result of the merger.

Next Steps

• Initiate toxicology studies for SIL-204.
• Submit CTA in the EU for Phase 2/3 trial of SIL-204.
• Initiate Phase 2/3 trial of SIL-204 in patients with locally advanced pancreatic cancer in the EU in 2026.

Key Dates

Keywords

KRAS, siRNA, oncology, pancreatic cancer, SIL-204, LODER, Biomotion Sciences, Moringa Acquisition Corp, Business Combination, RNAi therapeutics